SpotOn Therapeutics

Eyeglasses for Alleviating Symptoms of Chronic Dizziness

Health Tech & Life Sciences
Non Active, Dec 2019 ceased to operate

Company Overview

Snapshot

Founded in February 2010 by Yoav Kahane, SpotOn Therapeutics operated with 1–10 employees. The company ceased operations in December 2019, following a pilot study in October 2018 that explored a novel eyeglasses solution for chronic dizziness.

Business overview

SpotOn Therapeutics developed and offered a noninvasive treatment for chronic dizziness, vertigo, and balance disorders. Its core technology, implemented in eyeglasses-like devices called Neuro-Balance Active Spots (NBA Spots), used active signals embedded in the lenses. These semitransparent NBA Spots were custom-fitted for each patient, adapting their position, size, and shape to individual needs without affecting normal vision. The company served the healthcare market, specifically targeting patients suffering from chronic dizziness, and operated within the Digital Therapeutics sector in Health Tech & Life Sciences.

Strategic signal

In October 2018, a pilot study was published on PubMed investigating SpotOn Therapeutics' novel eyeglasses for chronic dizziness. This publication provided early validation for the company's non-invasive approach to treating balance disorders, indicating potential for a new therapeutic avenue in the digital health and medical technologies sector.

Company Intelligence Q&A

What is SpotOn Therapeutics' primary focus?
SpotOn Therapeutics focuses on developing noninvasive treatments for chronic dizziness, vertigo, and balance disorders using specialized eyeglasses.
When was SpotOn Therapeutics founded?
SpotOn Therapeutics was founded in February 2010.
What is the core technology behind SpotOn Therapeutics' product?
The core technology involves Neuro-Balance Active Spots (NBA Spots), which are active signals embedded in eyeglasses lenses, custom-fitted to alleviate dizziness symptoms.
What was a key development for SpotOn Therapeutics in October 2018?
In October 2018, a pilot study was published on PubMed, evaluating the effectiveness of SpotOn Therapeutics' novel eyeglasses for chronic dizziness.
What is the current operational status of SpotOn Therapeutics?
SpotOn Therapeutics ceased to operate in December 2019.

External links